Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4959287 | 0.88 | MAPK1 (0.56) | SMN1; SMN2NPC1RAB9AMAPK1TSHR | |
| SCHEMBL4777062 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AMAPK1TSHR | |
| SCHEMBL4779029 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AMAPK1TSHR | |
| SCHEMBL4779874 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AMAPK1TSHR | |
| SCHEMBL4726533 | 0.82 | RAB9A (0.64) | SMN1; SMN2NPC1RAB9AMAPK1TSHR | |
| SCHEMBL4865927 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AGAALMNA | |
| SCHEMBL1742457 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AMAPK1GAA | |
| SCHEMBL4836394 | 0.78 | MAPT (0.47) | SMN1; SMN2NPC1RAB9AGAALMNA | |
| SCHEMBL4779136 | 0.77 | GRM5 (0.47) | SMN1; SMN2NPC1RAB9AMAPK1GAA | |
| SCHEMBL27782870 | 0.77 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716320-B2 | Antibacteriall heterocyclic ureas | REPLIDYNE, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20080207703-A1 | Antibacterial heterocyclic ureas | REPLIDYNE, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008011191-A1 | ANTIBACTERIAL HETEROCYCLIC UREAS | REPLIDYNE, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207703-A1 | Antibacterial heterocyclic ureas | UMPS, UROD, UGP2 | SMN1; SMN2 4077/4885NPC1 2049/4885RAB9A 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.